REGENERON PHARMACEUTICALS
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
CHUGAI
Chugai specializes in prescription drugs and deliver innovative pharmaceuticals to patients around the world.
As a research and development-oriented pharmaceutical company, we boast the No. 1 market share in Japan for antibody drugs. We are developing innovative new drugs for diseases for which effective treatments have not yet been established, addressing unmet medical needs.
argenx
QuidelOrtho
QuidelOrtho’s Specialty Products Group (SPG) is your option for diagnostics and laboratory products for complement system protein analysis, including ELISAs, multiplex, antibodies, proteins, and reagents.. For further details, visit https://www.quidelortho.com
NOVARTIS
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
SVAR
We Provide Answers – It’s in Our Name
Did you know that Svar means Answers in Swedish? We provide cutting-edge products, versatile assay solutions, and services that help our clients get the answers they need for their drug development or basic research projects.
Our long experience in assay development, bioanalysis, and clinical diagnostics makes us an ideal partner for pharma, biotech, and CROs.
We also offer tools for the diagnosis, prognosis and monitoring of inflammatory and related diseases, which provide doctors with the answers they need to give their patients the right treatment at the right time.
So, whether you are helping patients by developing new drugs or diagnosing disease, we can help you get the answers you need. It’s in our name.
THE EUROPEAN FEDERATION OF IMMUNOLOGICAL SOCIETIES
The European Federation of Immunological Societies (EFIS) is the umbrella organization of 35 European national immunological societies and associations – collectively uniting more than 14,000 individual scientists and clinicians – whose mission is to advance education, training, research and collaboration in immunology and related fields. EFIS’ partner journal, the European Journal of Immunology (EJI), has since 1971 been serving the needs of the immunology community worldwide with objective enthusiasm, focusing on various aspects of basic, clinical and translational immunology. Together, EFIS-EJI are proud to offer financial support to the organizers of high-caliber immunology-themed meetings, workshops and schools that are organized in Europe and are international in nature. Specifically, through its support, the EFIS-EJI partnership aims to enhance interaction between young scientists and established immunologists, by providing funding to offset the participation costs of deserving junior researchers who, without such support, would be unable to attend quality events focusing on immunology and related disciplines. For further details, visit https://efis.org
Johnson & Johnson
Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives. With rigorous science and compassion, we confidently address the most complex diseases of our time and unlock the medicines of tomorrow. Therapeutic areas include: Oncology, Immunology, Neuroscience, Cardiopulmonary and Specialty ophthalmology.
HycultBiotech
We are proud to be a leading manufacturer of innate immunity research reagents, with a special focus on complement pathways. Our mission has always been to find answers to your questions and work towards improving health. We have been fulfilling this mission since 1994. Our team possesses extensive expertise in the development and production of assays, antibodies, and proteins. We are committed to supporting scientists worldwide in their research on human diseases. For further details, visit https://www.hycultbiotech.com
THE ANTIBODY SOCIETY
The Antibody Society is an international non-profit association representing individuals and organizations involved in antibody research and development. We engage in activities that broadly benefit our members, and we encourage collaboration between companies, academia and government organizations in the antibody field. We are an authoritative source of information about antibody therapeutics development, which we disseminate via our website, presentations and publications. We also help to organize conferences on topics relevant to antibody research and development. As a global association, the Society can engage with government and international agencies such as the World Health Organization, to discuss issues of importance to the antibody community.
